- Home
- PRCT vs ORIC Comparison
PRCT vs ORIC Comparison
Compare PRCT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCT | ORIC |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRCT | ORIC |
|---|---|---|
| Price | $19.28 | $12.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $35.44 | $19.73 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.71 | ★ 19.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $308,054,000.00 | N/A |
| Revenue This Year | $31.34 | N/A |
| Revenue Next Year | $24.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $16.67 | $7.23 |
| 52 Week High | $40.10 | $14.93 |
Technical Indicators
Market Signals| Indicator | PRCT | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 45.46 |
| Support Level | $16.89 | $10.67 |
| Resistance Level | $29.27 | $12.57 |
| Average True Range (ATR) | 1.13 | 0.59 |
| MACD | -0.21 | -0.19 |
| Stochastic Oscillator | 1.94 | 20.92 |
Price Performance
Historical ComparisonAbout PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.